anti-Bcr antibody product blog
Tags: Antibody; Polyclonal Antibody; BCR; anti-Bcr antibody;
The Bcr n/a (Catalog #MBS614496) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Bcr (Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, BCR1, D22S11) reacts with Human, Mouse, Rat and may cross-react with other species as described in the data sheet. MyBioSource\'s Bcr can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB), Immunocytochemistry (ICC), Flow Cytometry (FC/FACS).Suitable for use in ELISA, Flow Cytometry, Western Blot and Immunocytochemistry.
Dilution: Western Blot: 1:1000
Immunocytochemistry: 1:100
Flow Cytometry: 1:25. Researchers should empirically determine the suitability of the Bcr n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The Bcr n/a product has the following accession number(s) (GI #179750). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the Bcr (Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, BCR1, D22S11) with the following immunoassay(s):
Western Blot (WB) (Western blot analysis of extracts from K562, MCF-7 and HepG2 cells, using Bcr Antibody.)
Immunofluorescence (IF) (Immunofluorescent staining of PAE cells, using MBS614496 (left) and the same antibody preincubated with Bcr-specific peptide (right).)
Flow Cytometry (FC/FACS) (Flow cytometric analysis of MBS614496 staining of untreated (green) or STI571 treated (blue) K562 cells compared to a nonspecific negative control antibody (red).)
The Bcr gene was orginally identified by its presence in the chimeric Bcr-Abl oncogene (1). The N-terminal part of Bcr contains an oligomerization domain, a serine/threonine kinase domain and a region that binds SH2 domain. The middle of the protein has a PH domain and a region of sequence similarity to the guanine nucleotide exchange factors for the Rho family of GTP binding proteins. The C-terminal part may be involved in a GTPase-activating function for the small GTP-binding protein Rac (2,3). The function of Wildtype Bcr in cells remains unclear. PDGF receptor may use Bcr as a downstrean signal mediator (4). The Bcr-Abl fusion results in production of a constitutively active tyrosine kinase, which causes chronic myelogenous leukemia (CML) (5). Tyrosine 177 of Bcr is phosphorylated in Bcr-Abl fusion protein, which plays an important role in transforming the activity of Bcr-Abl.
Immunogen: Synthetic peptide (KLH coupled) corresponding to the N-terminal sequence of human Bcr. MW of Antigen: 130, 160kD. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Bcr are readily searchable from our website. Different antibodies against the same target such as Bcr may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.